Drug intelligence / Profile preview

Yiqi Tongyang Prescription

Development stage: Preclinical
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Yiqi Tongyang Prescription is a Traditional Chinese Medicine (TCM) formulation currently under investigation for the treatment of chronic immune thrombocytopenia. The name "Yiqi Tongyang" translates to "replenishing qi and warming yang," indicating its intended therapeutic approach within TCM principles. A specific formulation, Yiqi Tongyang granules, is being developed and studied for this indication.

Other names: Yiqi Tongyang granules

Targets

IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Yiqi Tongyang Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiqi Tongyang Prescription.

Explore the full profile